Abstract
Irinotecan is a drug commonly used for the treatment of cancer patients, both as a single agent or in combination therapy. Neutropenia and diarrhea are the dose-limiting toxicities. Genetic variations of proteins involved in irinotecan metabolism and transport have been considered in the development of irinotecan toxicity. In particular, polymorphisms affecting UDP- glucuronosyltransferase isoform 1A1 (UGT1A1) expression or activity are being investigated. Among these, UGT1A1*28 has been considered as the major predictive pharmacogenetic marker for severe hematological toxicity (neutropenia). However, translation to clinical practice of UGT1A1*28 testing as a predictive marker of adverse effects needs to be further investigated and the available data are not conclusive in defining a precise genotype-based dosage. Further prospective studies are required to reach a personalization of chemotherapy with irinotecan.
| Original language | English |
|---|---|
| Pages (from-to) | 158-165 |
| Number of pages | 8 |
| Journal | Journal of Chemotherapy |
| Volume | 20 |
| Issue number | 2 |
| Publication status | Published - Apr 2008 |
Keywords
- APC: 7-ethyl-10-[4-N-(5-amino pentanoic acid)-1-piperidino]- carbonyloxycamptothecin
- CRC: Colorectal cancer
- hCE: Human carboxylesterases
- NPC: 7-ethyl-10-[4-(1-piperidino)-1-amino]- carbonyloxycamptothecin
- SN38: 7-ethyl-10-hydroxycamptothecin
ASJC Scopus subject areas
- Pharmacology (medical)
- Microbiology (medical)
- Medicine(all)